New Delhi, May 12 -- In recent order announced by the US President Donald Trump which aims to slash prescriptive drug prices in the United States to be lowered by up to 80 per cent, is likely to create ripple effect in the Global pharmaceutical landscape, raising alarms about potential repercussions for India's pharmaceutical policies, according to a report by Global Trade Research Initiative (GTRI).

Trump's "Most Favored Nation" (MFN) pricing rule will make U.S as the lowest charged country in terms of U.S. drug prices, while this move could lower costs for American patients, it's expected to pressure pharmaceutical companies to seek higher revenues elsewhere, potentially targeting markets like India.

"I am pleased to announce that Tom...